An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2- Period, Crossover Study to Evaluate Bioequivalence Between YHP2407 and YHR2502 in Healthy Subjects
Latest Information Update: 21 May 2025
At a glance
- Drugs YHP-2407 (Primary) ; YHR-2502
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Yuhan
Most Recent Events
- 13 May 2025 Status changed from recruiting to completed.
- 21 Apr 2025 New trial record